Evoke Pharma Inc
EVOK5.158USD
+0.468+9.98%
Market hours （ET）Quotes delayed by 15 min
7.70MMarket Cap
LossP/E TTM
More Details of Evoke Pharma Inc Company
Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. The Company operates through the development and commercialization of pharmaceutical products. It is developing its product, Gimoti (metoclopramide) nasal spray, the first and only nasally administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. It developed Gimoti, a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a novel formulation of metoclopramide offering systemic delivery by nasal spray administration. It has developed the nasal formulation of metoclopramide to provide its targeted patient population with acute or recurrent symptoms of diabetic gastroparesis.
Company Info
Ticker SymbolEVOK
Company nameEvoke Pharma Inc
IPO dateSep 25, 2013
CEOMr. Matthew J. (Matt) D'Onofrio
Number of employees3
Security typeOrdinary Share
Fiscal year-endSep 25
Address420 Stevens Avenue
CitySOLANA BEACH
Stock exchangeLondon Stock Exchange
CountryUnited States of America
Postal code92075
Phone18583451494
Websitehttps://evokepharma.com/
Ticker SymbolEVOK
IPO dateSep 25, 2013
CEOMr. Matthew J. (Matt) D'Onofrio
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Matthew J. (Matt) D'Onofrio
Mr. Matthew J. (Matt) D'Onofrio
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
9.82K
+15.50%
Mr. Cam L. Garner
Mr. Cam L. Garner
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
2.33K
-0.04%
Dr. Malcolm R. Hill, Pharm.D.
Dr. Malcolm R. Hill, Pharm.D.
Independent Director
Independent Director
133.00
-0.75%
Dr. Todd C. Brady, M.D., Ph.D.
Dr. Todd C. Brady, M.D., Ph.D.
Independent Director
Independent Director
27.00
-3.57%
Mr. Greg Pyszcymuka
Mr. Greg Pyszcymuka
Independent Director
Independent Director
--
--
Dr. Kenneth Jon (Ken) Widder, M.D.
Dr. Kenneth Jon (Ken) Widder, M.D.
Independent Director
Independent Director
--
--
Dr. Marilyn R. Carlson, M.D.
Dr. Marilyn R. Carlson, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Benjamin C. (Ben) Smeal
Mr. Benjamin C. (Ben) Smeal
Independent Director
Independent Director
--
--
Mr. Daniel Kontoh-Boateng
Mr. Daniel Kontoh-Boateng
Investor Contact
Investor Contact
--
--
Ms. Vickie W. Reed
Ms. Vickie W. Reed
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Matthew J. (Matt) D'Onofrio
Mr. Matthew J. (Matt) D'Onofrio
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
9.82K
+15.50%
Mr. Cam L. Garner
Mr. Cam L. Garner
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
2.33K
-0.04%
Dr. Malcolm R. Hill, Pharm.D.
Dr. Malcolm R. Hill, Pharm.D.
Independent Director
Independent Director
133.00
-0.75%
Dr. Todd C. Brady, M.D., Ph.D.
Dr. Todd C. Brady, M.D., Ph.D.
Independent Director
Independent Director
27.00
-3.57%
Mr. Greg Pyszcymuka
Mr. Greg Pyszcymuka
Independent Director
Independent Director
--
--
Dr. Kenneth Jon (Ken) Widder, M.D.
Dr. Kenneth Jon (Ken) Widder, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q1
FY2024
FY2024Q1
FY2023
FY2022
FY2021
FY2020
No Data
By RegionUSD
Name
Revenue
Proportion
United States
3.08M
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 24
Updated: Sat, May 24
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Nantahala Capital Management, LLC
9.92%
Bleichroeder LP
4.61%
Citadel Advisors LLC
1.66%
D'Onofrio (Matthew J)
0.66%
Geode Capital Management, L.L.C.
0.53%
Other
82.62%
Shareholders
Shareholders
Proportion
Nantahala Capital Management, LLC
9.92%
Bleichroeder LP
4.61%
Citadel Advisors LLC
1.66%
D'Onofrio (Matthew J)
0.66%
Geode Capital Management, L.L.C.
0.53%
Other
82.62%
Shareholder Types
Shareholders
Proportion
Hedge Fund
11.60%
Investment Advisor
4.62%
Individual Investor
1.34%
Investment Advisor/Hedge Fund
0.70%
Other
81.74%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
34
272.65K
18.26%
-174.03K
2025Q1
37
273.02K
18.29%
-164.20K
2024Q4
38
286.68K
19.29%
-150.95K
2024Q3
39
276.54K
27.87%
-57.30K
2024Q2
39
330.88K
325.68%
-1.95K
2024Q1
46
331.84K
45.81%
+48.22K
2023Q4
42
12.65K
4.52%
-4.41K
2023Q3
46
12.52K
4.50%
-16.16K
2023Q2
47
11.87K
4.27%
-16.69K
2023Q1
53
12.69K
4.56%
-16.37K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Nantahala Capital Management, LLC
148.15K
9.92%
--
--
Mar 31, 2025
Bleichroeder LP
68.75K
4.61%
--
--
Mar 31, 2025
Citadel Advisors LLC
24.80K
1.66%
+24.80K
--
Mar 31, 2025
D'Onofrio (Matthew J)
9.82K
0.66%
+1.32K
+15.50%
Mar 24, 2025
Geode Capital Management, L.L.C.
7.93K
0.53%
--
--
May 31, 2025
Kowieski (Mark A.)
4.92K
0.33%
+4.92K
--
Mar 24, 2025
The Vanguard Group, Inc.
2.49K
0.17%
--
--
May 31, 2025
Gonyer (David A)
2.36K
0.16%
-1.00
-0.04%
Mar 24, 2025
Garner (Cam L)
2.33K
0.16%
-1.00
-0.04%
Mar 24, 2025
Carlson (Marilyn R.)
360.00
0.02%
--
--
Mar 24, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 30, 2024
Merger
12<1
Jul 30, 2024
Merger
12<1
Jul 30, 2024
Merger
12<1
Jul 30, 2024
Merger
12<1
May 20, 2022
Merger
12<1
May 20, 2022
Merger
12<1
Date
Type
Ratio
Jul 30, 2024
Merger
12<1
Jul 30, 2024
Merger
12<1
Jul 30, 2024
Merger
12<1
Jul 30, 2024
Merger
12<1
May 20, 2022
Merger
12<1
May 20, 2022
Merger
12<1
May 20, 2022
Merger
12<1
May 20, 2022
Merger
12<1
